<DOC>
	<DOCNO>NCT01753193</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety MEDI-546 adult moderate severe active systemic lupus erythematosus</brief_summary>
	<brief_title>An Open-label Study Evaluate Long-term Safety MEDI-546 , Treatment SLE , Adults</brief_title>
	<detailed_description>This open-label extension study evaluate long-term safety tolerability intravenous ( IV ) MEDI-546 adult subject moderately-to-severely active systemic lupus erythematosus ( SLE ) . Subjects must complete qualify Phase 2 study meet study criterion order eligible .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Must willing use 2 method effective contraception Must venous access Must willing forego participation clinical trial SLE . Any concurrent condition opinion investigator would interfere evaluation investigational product Major surgery within 8 week sign ICF Elective major surgery plan study period Concomitant Medications within last 12 week : Azathioprine &gt; 200 mg/day , Mycophenolate mofetil/mycophenolic acid &gt; 2.0 g/day , Oral , SC , intramuscular methotrexate &gt; 25 mg/week A live attenuate vaccine within 4 week sign ICF Bacillus Calmette Gu√©rin ( BCG ) vaccine within 1 year ICF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
</DOC>